Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Cited by (998)

Items 101–200 of 998

1. Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
   Sun, Feng, Chai, Sanbao, Yu, Kai, Quan, Xiaochi, Yang, Zhirong, Wu, Shanshan, Zhang, Yuan, Ji, Linong, Wang, Jun, Shi, Luwen · 2015 · Diabetes Technology & Therapeutics
2. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
   Baptist Gallwitz, Juan Guzman, Francesco Dotta, Bruno Guerci, Rafael Simó, Bruce R. Basson, Andreas Festa, Jacek I. Kiljanski, Hélène Sapin, MICHAEL E. TRAUTMANN et al. · 2012 · The Lancet
3. Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
   Gier, Belinda, Butler, Peter C., Lai, Chi K., Kirakossian, David, DeNicola, Matthew M., Yeh, Michael W. · 2012 · The Journal of Clinical Endocrinology & Metabolism
4. Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials
   John B. Buse, Alan J. Garber, Julio Rosenstock, Wolfgang Ekkehard Schmidt, Jason Brett, Nicoline Videbæk, Jens Juul Holst, Michael Albrecht Nauck · 2011 · The Journal of Clinical Endocrinology & Metabolism
5. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
   Weiss, Tracey, Yang, Lingfeng, Carr, Richard D, Pal, Sampriti, Sawhney, Baanie, Boggs, Robert, Rajpathak, Swapnil, Iglay, Kristy · 2022 · BMJ Open Diabetes Research & Care
6. Pharmacotherapy of type 2 diabetes: An update and future directions
   Antea J. DeMarsilis, Niyoti Reddy, Chrysoula Boutari, Andreas Filippaios, Elliot Sternthal, Niki Katsiki, Christos Socrates Mantzoros · 2022 · Metabolism
7. Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes ( AWARD ‐5): a randomized, phase III study
   Ruth S. Weinstock, Bruno Guerci, Guillermo E. Umpierrez, Michael Albrecht Nauck, Zachary Skrivanek, Zvonko Miličević · 2015 · Diabetes Obesity and Metabolism
8. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model
   Liping Zhang, Lingyu Zhang, Lin Li, Christian Hölscher · 2018 · Neuropeptides
9. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
   Ahren, Bo · 2013 · Vascular Health and Risk Management
10. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
    Asger Lund, Filip Krag Knop, Tina Vilsbøll · 2014 · European Journal of Internal Medicine
11. The effect of glucagon-like peptide 1 on cardiovascular risk
    Jacob Sivertsen, Jaya Birgitte Rosenmeier, Jens Juul Holst, Tina Vilsbøll · 2012 · Nature Reviews Cardiology
12. Liraglutide: A New Option for the Treatment of Obesity
    Wesley A. Nuffer, Jennifer M. Trujillo · 2015 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
13. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials
    Matteo Monami, Niccolò Marchionni, Edoardo Mannucci · 2009 · European Journal of Endocrinology
14. The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
    Madsbad, S. · 2014 · Diabetes, Obesity and Metabolism
15. Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)
    Bolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., Hanefeld, M. · 2014 · Diabetic Medicine
16. Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]
    Sachiko Hattori · 2010 · Endocrine Journal
17. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
    Joshua J. Neumiller · 2009 · Journal of the American Pharmacists Association
18. Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the <scp>LEAD</scp> ‐2 study
    Nauck, M., Frid, A., Hermansen, K., Thomsen, A. B., During, M., Shah, N., Tankova, T., Mitha, I., Matthews, D. R. · 2013 · Diabetes, Obesity and Metabolism
19. Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets
    Sloop, Kyle W., Willard, Francis S., Brenner, Martin B., Ficorilli, James, Valasek, Kathleen, Showalter, Aaron D., Farb, Thomas B., Cao, Julia X.C., Cox, Amy L., Michael, M. Dodson et al. · 2010 · Diabetes
20. Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial
    Nauck, Michael, Rizzo, Manfredi, Johnson, Andrew, Bosch-Traberg, Heidrun, Madsen, Jesper, Cariou, Bertrand · 2016 · Diabetes Care
21. Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
    Gallwitz, Baptist · 2011 · Drugs
22. Targeting the glucagon receptor family for diabetes and obesity therapy
    Young Min Cho, Catherine E. Merchant, Timothy J. Kieffer · 2012 · Pharmacology & Therapeutics
23. Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
    Elizabeth S. Mearns, Diana M Sobieraj, Charles Michael White, Whitney J Saulsberry, Christine G. Kohn, Yunes Doleh, E. Zaccaro, Craig Ian Coleman · 2015 · PLoS ONE
24. Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
    M. Katout, Hong Zhu, Jessica Rutsky, P. Shah, Robert D. Brook, Jixin Zhong, Sanjay Rajagopalan · 2013 · American Journal of Hypertension
25. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
    Koliaki, Chrysi, Doupis, John · 2011 · Diabetes Therapy
26. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue
    Russell-Jones, David · 2009 · Molecular and Cellular Endocrinology
27. Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes
    Carls, Ginger S., Tuttle, Edward, Tan, Ruo-Ding, Huynh, Johnny, Yee, John, Edelman, Steven V., Polonsky, William H. · 2017 · Diabetes Care
28. GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
    María Isabel Del Olmo-García, Juan Francisco Merino-Torres · 2018 · Journal of Diabetes Research
29. Adipose tissue in obesity and obstructive sleep apnoea
    Maria Rosaria Bonsignore, Walter T. McNicholas, Josep Maria Montserrat, Jürgen Eckel · 2011 · European Respiratory Journal
30. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
    Blüher, Matthias, Rosenstock, Julio, Hoefler, Josef, Manuel, Raymond, Hennige, Anita M. · 2024 · Diabetologia
31. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
    An Tang, RÉMI P.R. RABASA-LHORET, Hélène Castel, Claire Wartelle‐Bladou, Guillaume Gilbert, Karine Massicotte-Tisluck, Gabriel Chartrand, Damien Olivié, Anne‐Sophie Julien, Jacques A. de Guise et al. · 2015 · Diabetes Care
32. Metformin Protects against Oxidative Stress Injury Induced by Ischemia/Reperfusion via Regulation of the lncRNA-H19/miR-148a-3p/Rock2 Axis
    Jing Zeng, Long Zhu, Jing Liu, Tao Zhu, Zhaohui Xie, Xiaoou Sun, Hao Zhang · 2019 · Oxidative Medicine and Cellular Longevity
33. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study
    Matikainen, Niina, Söderlund, Sanni, Björnson, Elias, Pietiläinen, Kirsi, Hakkarainen, Antti, Lundbom, Nina, Taskinen, Marja‐Riitta, Borén, Jan · 2019 · Diabetes, Obesity and Metabolism
34. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway
    R. Kimura, Masahiro Okouchi, H. Fujioka, A. Ichiyanagi, Fumie Ryuge, T. Mizuno, K. Imaeda, Naotsuka Okayama, Y. Kamiya, Kiyofumi Asai et al. · 2009 · Neuroscience
35. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
    Brendan McIntosh, Chris G Cameron, Sumeet R. Singh, Changhua Yu, Tarun K. Ahuja, Nicky J. Welton, Marshall Dahl · 2011 · Europe PMC (PubMed Central)
36. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results
    Sten Madsbad · 2009 · Best Practice & Research Clinical Endocrinology & Metabolism
37. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in <scp>J</scp> apanese people with type 2 diabetes
    Seino, Yutaka, Terauchi, Yasuo, Osonoi, Takeshi, Yabe, Daisuke, Abe, Nobuyuki, Nishida, Tomoyuki, Zacho, Jeppe, Kaneko, Shizuka · 2018 · Diabetes, Obesity and Metabolism
38. Salba-chia (Salvia hispanica L.) in the treatment of overweight and obese patients with type 2 diabetes: a double-blind randomized controlled trial
    Vuksan, V., Jenkins, A.L., Brissette, C., Choleva, L., Jovanovski, E., Gibbs, A.L., Bazinet, R.P., Au-Yeung, F., Zurbau, A., Ho, H.V.T. et al. · 2017 · Nutrition, Metabolism and Cardiovascular Diseases
39. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity
    Gault, Victor A., Kerr, Barry D., Harriott, Patrick, Flatt, Peter R. · 2011 · Clinical Science
40. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study
    Perna, Simone, Guido, Davide, Bologna, Chiara, Solerte, Sebastiano Bruno, Guerriero, Fabio, Isu, Antonio, Rondanelli, Mariangela · 2016 · Aging Clinical and Experimental Research
41. The Human GLP-1 Analog Liraglutide and the Pancreas
    Nyborg, Niels C.B., Mølck, Anne-Marie, Madsen, Lars W., Bjerre Knudsen, Lotte · 2012 · Diabetes
42. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta‐analysis
    Josefine E. Schopman, Airin C.R. Simon, Sanne Johanna Maria Hoefnagel, Joost B.L. Hoekstra, Rob J. P. M. Scholten, Frits Holleman · 2013 · Diabetes/Metabolism Research and Reviews
43. Incretin effect: GLP-1, GIP, DPP4
    Kyriakos Kazakos · 2011 · Diabetes Research and Clinical Practice
44. Update on incretin hormones
    Liza K. Phillips, Johannes B. Prins · 2011 · Annals of the New York Academy of Sciences
45. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta‐analysis of the liraglutide clinical trial programme
    Bernard Zinman, Wolfgang Ekkehard Schmidt, A C Moses, N. Lund, Stephen C. L. Gough · 2011 · Diabetes Obesity and Metabolism
46. Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease
    Masse, Karly E., Lu, Van B. · 2023 · Frontiers in Endocrinology
47. Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
    Hu, Weiting, Song, Rui, Cheng, Rui, Liu, Caihong, Guo, Rui, Tang, Wei, Zhang, Jie, Zhao, Qian, Li, Xing, Liu, Jing · 2022 · Frontiers in Endocrinology
48. Diabesity: therapeutic options
    Stephen Colagiuri · 2009 · Diabetes Obesity and Metabolism
49. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
    Robert A. Scott, Daniel F. Freitag, Li Li, Audrey Y. Chu, Praveen Surendran, Robin Young, Niels Grarup, Alena Stančáková, Yuning Chen, Tibor V. Varga et al. · 2016 · Science Translational Medicine
50. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
    Christoph Kapitza, Kirsten Dahl, Jacob Bonde Jacobsen, Mads Buhl Axelsen, Anne Flint · 2017 · Diabetologia
51. Bariatric Surgery in Class I Obesity: A Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
    Busetto, Luca, Dixon, John, De Luca, Maurizio, Shikora, Scott, Pories, Walter, Angrisani, Luigi · 2014 · Obesity Surgery
52. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
    Jensterle, Mojca, Kravos, Nika Aleksandra, Pfeifer, Marija, Kocjan, Tomaz, Janez, Andrej · 2015 · Hormones
53. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus
    Eduard Montanya, Giorgio Sesti · 2009 · Clinical Therapeutics
54. Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
    Michael Albrecht Nauck, Robert E. Ratner, Christoph Kapitza, Rachele Berria, Mark N. Boldrin, R. Balena · 2009 · Diabetes Care
55. The effects of glucagon‐like peptide‐1 on the beta cell
    Tina Vilsbøll · 2009 · Diabetes Obesity and Metabolism
56. GLP‐1 based therapies: differential effects on fasting and postprandial glucose
    Mark S. Fineman, Brenda B. Cirincione, David G. Maggs, Michaëla Diamant · 2012 · Diabetes Obesity and Metabolism
57. The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review
    Vanita R. Aroda, Robert E. Ratner · 2011 · Diabetes/Metabolism Research and Reviews
58. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
    Matteo Monami, Francesco Cremasco, Caterina Lamanna, Claudia Colombi, Carla Maria Desideri, Iacopo Iacomelli, Niccolò Marchionni, Edoardo Mannucci · 2011 · Experimental Diabetes Research
59. A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes
    Walid K. H. Fakhoury, C LeReun, Donna Wright · 2010 · Pharmacology
60. Safety and efficacy of insulin degludec/liraglutide ( ID egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
    Helena W. Rodbard, Bruce W. Bode, Stewart B. Harris, Ludger Rose, Lucine Lehmann, Henrik Jarlov, Jerry Thurman, the Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators · 2016 · Diabetic Medicine
61. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
    Bernard Zinman, Steven P. Marso, Erik Christiansen, Salvatore Calanna, Søren Rasmussen, John B. Buse · 2018 · Diabetes Care
62. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
    Levin, Philip A, Nguyen, Hiep, Wittbrodt, Eric, Kim, Seoyoung C. · 2017 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
63. Incretin-Based Therapies: Review of Current Clinical Trial Data
    Anne L. Peters · 2010 · The American Journal of Medicine
64. GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
    Mundil, Dhanwantee, Cameron-Vendrig, Alison, Husain, Mansoor · 2012 · Diabetes and Vascular Disease Research
65. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial
    Andrew Ahmann, Helena W. Rodbard, Julio Rosenstock, Jorma T. Lahtela, Luis De Loredo, Karen Tornøe, A. Boopalan, Michael Albrecht Nauck, on behalf of the NN2211‐3917 Study Group · 2015 · Diabetes Obesity and Metabolism
66. Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.
    Kelvin Tran, Young In Park, Shalin Pandya, Navin John Muliyil, Brandon David Jensen, Kovin Huynh, Quang Phuong Huynh Nguyen · 2017 · PubMed Central
67. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies
    Steven P. Marso, Jason B. Lindsey, Joshua M. Stolker, John A. House, Gabriela Martinez Ravn, Kevin F. Kennedy, Troels Mygind Jensen, John B. Buse · 2011 · Diabetes and Vascular Disease Research
68. Targeting the incretin system in obesity and type 2 diabetes mellitus
    Saleem Ansari, Bernard Chong Eu Khoo, Tricia Tan · 2024 · Nature Reviews Endocrinology
69. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes
    ten Kulve, Jennifer S., Veltman, Dick J., van Bloemendaal, Liselotte, Barkhof, Frederik, Drent, Madeleine L., Diamant, Michaela, IJzerman, Richard G. · 2016 · Diabetes Care
70. Monotherapy with the once‐weekly GLP‐1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose‐dependent effects on glycaemic control in a randomized, double‐blind, placebo‐controlled study
    George Grunberger, A. Chang, G. Garcia Soria, Fady T. Botros, Rebhi Bsharat, Zvonko Miličević · 2012 · Diabetic Medicine
71. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
    Feng Sun, Sanbao Chai, Lishi Li, Kai Yu, Zhirong Yang, Shanshan Wu, Yuan Zhang, LINONG JI, Siyan Zhan · 2015 · Journal of Diabetes Research
72. GDF15 Induces an Aversive Visceral Malaise State that Drives Anorexia and Weight Loss
    Tito Borner, Hallie S. Wald, Misgana Y. Ghidewon, Bei Zhang, Zhidan Wu, Bart C. De Jonghe, Danna M. Breen, Harvey J. Grill · 2020 · Cell Reports
73. Liraglutide for Type 2 diabetes and obesity: a 2015 update
    Eva Winning Iepsen, Signe S. Torekov, Jens Juul Holst · 2015 · Expert Review of Cardiovascular Therapy
74. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
    Philip Home, Paramesh Shamanna, Murray W Stewart, Fang Yang, Michael J. Miller, Caroline Perry, Molly C. Carr · 2014 · Diabetes Obesity and Metabolism
75. Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    David J. Klein, Tadej Battelino, Dhruba J. Chatterjee, Lisbeth Vestergård Jacobsen, Paula M. Hale, Silva A Arslanian, on behalf of the NN2211-1800 Study Group · 2014 · Diabetes Technology & Therapeutics
76. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme
    Kevin Dean Niswender, Xavier Pi‐Sunyer, John B. Buse, Klaus H. Jensen, Anders Dyhr Toft, David L Russell-Jones, Bernard Zinman · 2012 · Diabetes Obesity and Metabolism
77. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: An updated meta-analysis of randomized controlled trials
    Cao, Chuqing, Yang, Shuting, Zhou, Zhiguang · 2019 · Endocrine
78. Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
    Uccellatore, Annachiara, Genovese, Stefano, Dicembrini, Ilaria, Mannucci, Edoardo, Ceriello, Antonio · 2015 · Diabetes Therapy
79. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
    Matteo Monami, Ilaria Dicembrini, Niccolò Marchionni, Carlo Maria Rotella, Edoardo Mannucci · 2012 · Experimental Diabetes Research
80. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials
    Vivian Andrew Fonseca, J. Hans DeVries, Robert R. Henry, Morten Donsmark, Henrik Frederik Thomsen, Jorge Plutzky · 2014 · Journal of Diabetes and its Complications
81. Harnessing glucagon‐like peptide‐1 receptor agonists for the pharmacological treatment of overweight and obesity
    Rémy Burcelin, Pierre Gourdy · 2016 · Obesity Reviews
82. Lipotoxicity and β Cell Maintenance in Obesity and Type 2 Diabetes
    Risheng Ye, Toshiharu Onodera, Philipp E. Scherer · 2019 · Journal of the Endocrine Society
83. Weight management in obesity – past and present
    David B Haslam · 2016 · International Journal of Clinical Practice
84. Hydrogen Sulfide and Sulfate Prebiotic Stimulates the Secretion of GLP-1 and Improves Glycemia in Male Mice
    Jennifer Pichette, Nancy Fynn-Sackey, Jeffrey Gagnon · 2017 · Endocrinology
85. Are targeted therapies for diabetic cardiomyopathy on the horizon?
    Mitchel Tate, David Grieve, Rebecca Helen Ritchie · 2017 · Clinical Science
86. Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis
    Vosoughi, Kia, Atieh, Jessica, Khanna, Lehar, Khoshbin, Katayoun, Prokop, Larry J., Davitkov, Perica, Murad, M. Hassan, Camilleri, Michael · 2021 · eClinicalMedicine
87. Association of Pancreatitis with Glucagon-Like Peptide-1 Agonist Use
    Sarah L. Anderson, Jennifer M. Trujillo · 2010 · Annals of Pharmacotherapy
88. Glucose-dependent insulinotropic polypeptide (GIP)
    Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, Matthias Blüher, Andreas L. Birkenfeld, Jonathan Edward Campbell, Matthew P. Coghlan, David D. D’Alessio, Carolyn Fiona Deacon, Stefano DelPrato et al. · 2025 · Molecular Metabolism
89. Incretin Effects on β-Cell Function, Replication, and Mass
    Garber, Alan J. · 2011 · Diabetes Care
90. Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus
    R. Keith Campbell · 2011 · Clinical Therapeutics
91. Best Practices in the Management of Overweight and Obesity
    Beverly G. Tchang, Katherine H. Saunders, Leon I. Igel · 2020 · Medical Clinics of North America
92. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
    Bikou, Alexia, Dermiki-Gkana, Foteini, Penteris, Michail, Constantinides, Theodoros K, Kontogiorgis, Christos · 2024 · Expert Opinion on Pharmacotherapy
93. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16‐week, randomized, double‐blind, active control trial *
    Wenying Yang, L. Chen, Qiuhe Ji, X. Liu, J. Ma, Nikhil Tandon, A Bhattacharyya, Ajay Kumar, K.-W. Kim, Kun‐Ho Yoon et al. · 2010 · Diabetes Obesity and Metabolism
94. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes
    Susana Ravassa, Amaia Zudaire, Richard David Carr, Javier Dı́ez · 2011 · American Journal of Physiology-Heart and Circulatory Physiology
95. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes
    Kohei Kaku, M. F. Rasmussen, Per Clauson, Yutaka Seino · 2009 · Diabetes Obesity and Metabolism
96. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients
    Flint, Anne, Kapitza, Christoph, Hindsberger, Charlotte, Zdravkovic, Milan · 2011 · Advances in Therapy
97. Weight maintenance: challenges, tools and strategies for primary care physicians
    Taraneh Soleymani, Sunil Daniel, William Timothy Garvey · 2015 · Obesity Reviews
98. The Effect of Liraglutide on Weight Loss in Women with Polycystic Ovary Syndrome: An Observational Study
    Christina Bording Rasmussen, Svend Lindenberg · 2014 · Frontiers in Endocrinology
99. Liraglutide and its Neuroprotective Properties—Focus on Possible Biochemical Mechanisms in Alzheimer’s Disease and Cerebral Ischemic Events
    Michał Wiciński, Maciej Władysław Socha, Bartosz Malinowski, Eryk Wódkiewicz, Maciej Walczak, Karol Maksymilian Górski, Maciej Słupski, Katarzyna Pawlak-Osińska · 2019 · International Journal of Molecular Sciences
100. Short-Term Effects of Liraglutide on Visceral Fat Adiposity, Appetite, and Food Preference: A Pilot Study of Obese Japanese Patients with Type 2 Diabetes
     Inoue, Kana, Maeda, Norikazu, Kashine, Susumu, Fujishima, Yuya, Kozawa, Junji, Hiuge-Shimizu, Aki, Okita, Kohei, Imagawa, Akihisa, Funahashi, Tohru, Shimomura, Iichiro · 2011 · Cardiovascular Diabetology